CAS: 449758-17-2; 1-(2-Tetrahydropyranyl)-1H-Pyrazole

该化合物是有机化合物,具有独特的结构特征,包括一个环和四氢-2H-pyran mothy,具有一种独特的结构特征,包括一个环和四氢-2H-pyran modio,这种化合物通常具有三环化合物的特性,例如极地溶剂中的中溶性,以及由于在pyrazole环中存在氮原子而可能具有的再活动性.四氢-2H-pyran组有助于其循环结构,这可以影响其化学再活动性和稳定性.氮和氧在结构中的存在都可能允许各种功能性群体发生转变,使其成为医药化学和材料科学应用的候选物.此外,这种性质的化合物可能表现出生物活动,尽管具体的药用特性需要进一步调查.总体来说,1(四氢-2H-pyran-2-yl)-1H-pyrazolle是一支多用途的松式猎,用于进一步化学探索和潜在应用.

英文名称1-(2-Tetrahydropyranyl)-1H-Pyrazole
中文名称1-(四氢-2H-吡喃-2-基)-1H-吡唑
IUPAC名称1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole
其它别名1-(2-四氢吡喃yl)-1H-吡唑; 1H-Pyrazole,1-(Tetrahydro-2H-Pyran-2-yl)-
CAS编号449758-17-2
MFCD编号:MFCD11044692
EINECS号:807-897-5
FDA UNII编号:B38PZM2479
分子式:C8H12N2O
分子量:152.2
产品CID: 1455658
产品分类有机原料→分子砌块→芳杂环类化合物→吡唑类化合物

相似结构搜索
InChIKey: IMZWSOSYNFVECD-UHFFFAOYSA-N
InChI=1/C8H12N2O/c1-2-7-11-8(4-1)10-6-3-5-9-10/h3,5-6,8H,1-2,4,7H2…
计算化学: 氢键受体数3.0氢键供体数0.0可旋转键数1.0

相似化合物

938066-17-2 82099-98-7 1448317-12-1

MSDS等安全信息

GHS象形图
GHS符号GHS07;
注释: Exclamation mark
危险类别特定目标器官毒性 - 单次接触类别3
皮肤腐蚀/刺激类别2
严重眼刺激类别2A
急性毒性类别4(吸入)
急性毒性类别4(经皮)
急性毒性类别4(经口)
警示词Warning(警告)
危险描述H335 |可能引起呼吸道刺激.
H315 |造成皮肤刺激.
H319 |造成严重眼刺激.
H332 |吸入有害.
H312 |皮肤接触有害.
H302 |吞咽有害.
防范说明P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
危险品标志Xi
安全声明H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
WGK Germany3

欧盟法规

REACH注册ECHA物质C&L通报

上下游产品

合成工艺路线路线简述

3,4-二氢-2H-吡喃置于吡唑,三氟乙酸体系中,化学反应生成 1-(四氢-2H-吡喃-2-基)-1H-吡唑
参考文献:Thrombin Inhibitors
标题:Thrombin Inhibitors
摘要:该发明的化合物在抑制凝血酶,治疗血液凝固和心血管疾病方面具有用处,并具有以下结构: 1 其中 R 3 为氢或卤素,U为n或ch.

海关参考信息

2905121000-正丙醇
2905130000-正丁醇
2909110000-乙醚
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:US-10087197-B2
优先权日:2012-05-21
标题:Selective extraction of anions from solution
发明人：MEZEI GELLERT
权利人:WESTERN MICHIGAN UNIV RESEARCH FOUNDATION
摘要:A method of selectively extracting anions from an aqueous solution using an anion encapsulating aggregate formed upon the addition of a solvent, a copper contributor, a hydroxide contributor, an optional counterion contributor, and at least one encapsulating anion to an aqueous solution containing the anions, or upon the addition of a solvent, a polymeric chain of [CuII(Î¼-OH)(Î¼-ea)]âˆž and optionally, a counterion contributor to the aqueous solution. The aggregates include compounds of the formula cis-CuIIx(OR1)y(R2ea)z, where R1 is H or an alkyl group, R2 is H, or an alkyl group or a charged group, ea is an encapsulating anion, and each of x, y, and z is equal to an integer between about 1 and 40, inclusive. In addition, anion encapsulating aggregates can be formed by synthesis with alternate encapsulating anions by substituting alternate encapsulating anions for the encapsulating anion incorporated in the aggregate.

专利号:US-2021238187-A1
优先权日:2017-04-11
标题:Aziridine containing epothilone analogs, methods of synthesis, methods of treatment, and drug conjugates
发明人：NICOLAOU KYRIACOS C; RHOADES DEREK; WANG YANGPING
权利人:UNIV RICE WILLIAM M
摘要:In one aspect, the present disclosure provides epothilone analogs of the formula: (I) wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein. Additionally, drug conjugates with cell targeting moieties of the compounds are also provided.

专利号:CN-117304111-A
优先权日:2023-09-27
标题:Synthesis method of darostaamine intermediate